NAMSA Acquires WuXi AppTec's U.S. MedTech Testing Facilities

Under the agreement, NAMSA will acquire WuXi AppTec facilities in Minnesota and Georgia.

Afbbf26 A1fb377164
WuXi AppTec

NAMSA, a medtech testing, clinical and regulatory consulting firm, has entered into a definitive agreement to acquire the U.S. medical device testing operations of WuXi AppTec, a global company that provides a portfolio of R&D and manufacturing services to the pharmaceutical and life science industries.

Under the agreement, NAMSA will acquire WuXi AppTec facilities in Minnesota and Georgia.

“We are extremely pleased to announce our agreement with WuXi AppTec, as it enables us to expand our portfolio of clinical research and testing solutions for clients,” remarked André-Michel Ballester, NAMSA CEO. “NAMSA and WuXi AppTec’s Medical Device Testing Operations have different areas of expertise but serve the same client base and will enhance the client experience by combining capabilities. Together, we look forward to accelerating MedTech innovation and helping Sponsors deliver life-saving medical technology throughout the world,” concluded Ballester.

NAMSA said its strategic outsourcing and in-house services help medtech companies mitigate risk, shorten time to market and enhance stakeholder value.

Both companies will work closely to ensure a smooth transition for employees and customers.

More in News